89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is BIO89-100, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop BIO89-100 for the treatment of severe hypertriglyceridemia. 89bio, Inc. was founded in 2018 and is based in San Francisco, California.